Results 11 to 20 of about 27,657 (222)

Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. [PDF]

PLoS ONE, 2011
To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events and mortality in patients using diabetes medication.The General Practice Research Database was used to identify inception cohorts of insulin and different ...
Arlene M Gallagher, Liam Smeeth, Suzie Seabroke, Hubert G M Leufkens, Tjeerd P van Staa   +4 more
doaj   +3 more sources

A systematic review and meta-analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D). [PDF]

Diabet Med
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Kelly M, Saluja S, Ellis HL, Jamil S, Whyte MB, Heald A.   +5 more
europepmc   +2 more sources

Possible modulation of the antidiabetic effect of rosiglitazone by buspirone

Bulletin of Faculty of Pharmacy Cairo University, 2012
Diabetes mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia resulting from relative or absolute insulin deficiency with or without insulin resistance. As anxiolytics may have influence on glycemic control in diabetics,
Wafaa R. Mohamed, Gamal A. El Sherbiny, Hala F. Zaki, Mostafa E. El Sayed   +3 more
doaj   +2 more sources

Rosiglitazone

Reactions Weekly, 2006
europepmc   +5 more sources

Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo

Pharmaceuticals, 2022
Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction.
Bennet Y. Weber, Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, Zoltán Giricz   +9 more
doaj   +1 more source

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients

Pharmaceuticals, 2023
Human studies on the effect of rosiglitazone on inflammatory bowel disease (IBD) are still lacking. We investigated whether rosiglitazone might affect IBD risk by using the reimbursement database of Taiwan’s National Health Insurance to enroll a ...
Chin-Hsiao Tseng
doaj   +1 more source

Beneficial Effects of Aerobic Exercise Training Combined with Rosiglitazone on Glucose Metabolism in Otsuka Long Evans Tokushima Fatty Rats [PDF]

Diabetes & Metabolism Journal, 2017
BackgroundRegular aerobic exercise is essential for the prevention and management of type 2 diabetes mellitus and may be particularly beneficial for those treated with thiazolidinediones, since it may prevent associated weight gain.
Shan-Ji Piao, So Hun Kim, Young Ju Suh, Seong-Bin Hong, Seong Hee Ahn, Da Hae Seo, In-Sun Park, Moonsuk Nam   +7 more
doaj   +1 more source

Involvement of Prolyl Hydroxylase Domain Protein in the Rosiglitazone-Induced Suppression of Osteoblast Differentiation. [PDF]

PLoS ONE, 2015
Rosiglitazone is a well-known anti-diabetic drug that increases insulin sensitivity via peroxisome proliferator-activated receptor γ (PPARγ) activation, but unfortunately it causes bone loss in animals and humans.
Ju-Hee Kang, Hyun Jeong Kwak, Hye-Eun Choi, Juyoung Kim, Sangmee Hong, Ok-Hee Kim, Byung Chul Oh, Hyae Gyeong Cheon   +7 more
doaj   +1 more source

Gene Expression Analyses in Models of Rosiglitazone-Induced Physiological and Pathological Mineralization Identify Novel Targets to Improve Bone and Vascular Health

Cells, 2023
Clinical studies revealed detrimental skeletal and vascular effects of the insulin sensitizer rosiglitazone. We have shown earlier that rosiglitazone accelerates osteoblast differentiation from human mesenchymal stem cells (hMSC) at the expense of ...
Claudia Bruedigam, Johannes P. T. M. van Leeuwen, Jeroen van de Peppel   +2 more
doaj   +1 more source

Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

Frontiers in Pharmacology, 2021
The clinical controversy of rosiglitazone as a hypoglycemic agent is potentially associated with heart failure, mainly due to its potent activation of peroxisome proliferator-activated receptor γ (PPARγ).
Xuemei Cao, Xuemei Cao, Min Mao, Min Mao, Junlin Diao, Junlin Diao, Yi Hou, Yi Hou, Hong Su, Hong Su, Yongjun Gan, Jibin Li, Xiaoyong Tong, Chaodong Wu, Zhong Zuo, Xiaoqiu Xiao, Xiaoqiu Xiao   +16 more
doaj   +1 more source